- Novartis positions itself as eye care giant with Alcon merger
- Novartis announces merger proposal for Alcon
- Walgreens puts its money where its mouth is with World AIDS Day campaign
- Medication adherence could be blockbuster for specialty
- Spending on lobbying shows healthcare cos.’ stake in healthcare reform
HUENENBERG, Switzerland Eye care company Alcon has appointed a new executive.
The Swiss drug maker announced Monday the appointment of Robert Karsunky as SVP and CFO, effective Nov. 1. He succeeds Richard Croarkin, who has served as Alcon’s CFO since August 2007.
Karsunky previously worked for Novartis as CFO in the consumer health division. Novartis became the majority shareholder of Alcon on Aug. 25, when it completed the acquisition of 52% of the company’s stock from Nestle. It now owns 77% of Alcon.